Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study

Autor: Johal S, Brannman L, Genestier V, Cawston H

Publikováno v: ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 97-109 (2024)

Sukhvinder Johal,1 Lance Brannman,2 Victor Genestier,3 Hélène Cawston4 1Oncology Market Access and Pricing, AstraZeneca, Cambridge, UK; 2Oncology Market Access and Pricing, AstraZeneca, Gaithersburg, MD, USA; 3Health Economic and Outcomes Research,

Externí odkaz: https://doaj.org/article/860e88176f0f4ae09c834b85b21ba78e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.

Autor: Munir T; Department of Haematology, Leeds Teaching Hospital NHS Trust, Leeds, UK., Genovez V; Health Economics & Market Access, Amaris Consulting, Lisbon, Portugal., Genestier V; Amaris Consulting, Toronto, Canada., Ryan K; Global Medical Affairs, AstraZeneca, Gaithersburg, MD, USA., Liljas B; Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USA., Gaitonde P; Oncology Market Access & Pricing, AstraZeneca, Gaithersburg, MD, USA.

Publikováno v: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2023 Jun; Vol. 23 (5), pp. 579-589. Date of Electronic Publication: 2023 Apr 10.

MSR11 Performance of Progression-Based and Time-to-Death Utility Analysis Methods and Their Implications on Economic Models: A Targeted Review

Autor: Hopmans Galofré, G., Clayson, M., Tanova-Yotova, N., Genestier, V.

Publikováno v: In Value in Health December 2023 26(12) Supplement:S395-S395

P56 Comparison of Methods for Incorporating Time-to-Event Outcomes in Budget Impact Analyses

Autor: Law-Koune, Q., Hopmans Galofré, G., Genestier, V., Clayson, M., Cawston, H., Borget, I.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S12-S13